- Home
- GAIN vs XNCR Comparison
GAIN vs XNCR Comparison
Compare GAIN & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAIN
- XNCR
- Stock Information
- Founded
- GAIN 2005
- XNCR 1997
- Country
- GAIN United States
- XNCR United States
- Employees
- GAIN N/A
- XNCR N/A
- Industry
- GAIN Finance: Consumer Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- GAIN Finance
- XNCR Health Care
- Exchange
- GAIN Nasdaq
- XNCR Nasdaq
- Market Cap
- GAIN 519.9M
- XNCR 565.1M
- IPO Year
- GAIN 2005
- XNCR 2013
- Fundamental
- Price
- GAIN $14.17
- XNCR $7.34
- Analyst Decision
- GAIN Hold
- XNCR Buy
- Analyst Count
- GAIN 2
- XNCR 8
- Target Price
- GAIN $13.50
- XNCR $26.43
- AVG Volume (30 Days)
- GAIN 140.6K
- XNCR 589.7K
- Earning Date
- GAIN 08-12-2025
- XNCR 08-06-2025
- Dividend Yield
- GAIN 15.73%
- XNCR N/A
- EPS Growth
- GAIN N/A
- XNCR N/A
- EPS
- GAIN 1.78
- XNCR N/A
- Revenue
- GAIN $93,662,000.00
- XNCR $153,876,000.00
- Revenue This Year
- GAIN $5.34
- XNCR N/A
- Revenue Next Year
- GAIN $5.29
- XNCR $28.84
- P/E Ratio
- GAIN $7.87
- XNCR N/A
- Revenue Growth
- GAIN 7.28
- XNCR 7.54
- 52 Week Low
- GAIN $11.42
- XNCR $7.07
- 52 Week High
- GAIN $15.34
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- GAIN 52.03
- XNCR 29.43
- Support Level
- GAIN $13.69
- XNCR $7.07
- Resistance Level
- GAIN $14.04
- XNCR $8.21
- Average True Range (ATR)
- GAIN 0.20
- XNCR 0.54
- MACD
- GAIN 0.01
- XNCR -0.20
- Stochastic Oscillator
- GAIN 75.44
- XNCR 3.34
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.